The current study was conducted to use the propagated Egyptian strain of pigeon pox Qaluobeia 2017 virus on primary chicken embryo fibroblast (CEF)  in preparation of tissue culture (VERO)  specific pigeon  pox  virus vaccine (PPV) for pigeons. The titer of this virus was 10 ^5.5 TCID₅₀ /ml at the 20^th passage, and induced an acceptable reaction when it was tested for pathogenicity in pigeons. After addition of an equal volume of Lactalbumin sucrose stabilizer the virus fluid was lyophilized showing titer of 10 ^5.0 TCID₅₀/ml in VERO cells.  Keeping quality control tests revealed that such vaccine was free from the foreign contaminants, safe and potent. The humoral antibody level in the serum of vaccinated pigeons was measured by serum neutralization test (SNT) which proved that the induced pigeon pox antibodies had 1.3 neuralizing index (NI) from the 2nd week and reached its peak (2.8 NI) at 4th week post vaccination. Pigeons withstand the inoculation with the virulent PPV after 3 weeks from vaccination with no symptoms of PPV disease on contrast to control non- vaccinated pigeons with protection percent 95%. This study recorded the production of a safe and potent PPVV from local PPV strain (Qaluobeia -2017) of less cost than that prepared on specific pathogenic free Embroynated chicken egg (SPF-ECE)